Cenobamate significantly improves seizure control in intellectually disabled patients with drug-resistant epilepsy and allows drug load reduction
IntroductionEpilepsy patients with intellectual disability often suffer from drug-resistant epilepsy (DRE), which severely affects patients’ quality of life. Cenobamate (CNB) is a recently approved novel and effective ASM that can achieve high rates of seizure freedom in previously drug-resistant pa...
Main Authors: | Anna-Lena Friedo, Benedikt Greshake, Konstantin L. Makridis, Hans-Beatus Straub |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-07-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2023.1209487/full |
Similar Items
-
Cenobamate (YKP3089) and Drug-Resistant Epilepsy: A Review of the Literature
by: Jamir Pitton Rissardo, et al.
Published: (2023-07-01) -
Safety and efficacy of cenobamate in patients with uncontrolled focal seizures - a review of the literature
by: Zofia Pietrzak, et al.
Published: (2022-02-01) -
Cenobamate as add-on therapy for drug resistant epilepsies: effectiveness, drug to drug interactions and neuropsychological impact. What have we learned from real word evidence?
by: Nicola Pietrafusa, et al.
Published: (2023-12-01) -
Cenobamate in refractory epilepsy: Overview of treatment options and practical considerations
by: Bettina Schmitz, et al.
Published: (2023-12-01) -
Cenobamate, a Sodium Channel Inhibitor and Positive Allosteric Modulator of GABA<sub>A</sub> Ion Channels, for Partial Onset Seizures in Adults: A Comprehensive Review and Clinical Implications
by: Dustin R. Latimer, et al.
Published: (2021-06-01)